当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析

上海医药

(601607)

  

流通市值:339.95亿  总市值:651.78亿
流通股本:19.32亿   总股本:37.03亿

上海医药(601607)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至2023年年度实现净利润51.67亿元,每股收益1.02元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至2023年年度最新股东权益8032609.30万元,未分配利润3382233.29万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至2023年年度最新总资产21197253.38万元,负债13164644.08万元。

利润表
报告期2023-12-312023-09-302023-06-302023-03-31
营业总收入260,295,088,943.53197,508,314,193.06132,592,157,323.3766,226,461,496.33
营业总成本253,008,863,712.03191,379,813,519.61128,205,807,529.4364,033,665,635.78
营业利润7,667,234,704.326,555,955,096.954,558,084,231.872,490,594,009
利润总额7,054,296,738.486,518,995,175.954,533,792,505.392,491,896,591.33
净利润5,166,570,284.264,953,768,221.763,417,001,019.981,953,045,694.63
其他综合收益-126,719,890.54-170,966,425.38-122,849,260.45-31,353,262.71
综合收益总额5,039,850,393.724,782,801,796.383,294,151,759.531,921,692,431.92
资产负债表
报告期2023-12-312023-09-302023-06-302023-03-31
流动资产合计162,433,862,348.46164,628,820,577.63164,781,723,168.36157,170,379,297.84
非流动资产合计49,538,671,418.3448,517,559,819.9948,535,981,670.148,865,419,982.59
资产总计211,972,533,766.8213,146,380,397.62213,317,704,838.46206,035,799,280.43
流动负债合计122,371,879,034.89122,429,675,081.73124,339,571,550.9114,301,935,555.32
非流动负债合计9,274,561,766.9810,573,071,743.3710,035,656,400.6111,852,996,832.91
负债合计131,646,440,801.87133,002,746,825.1134,375,227,951.51126,154,932,388.23
归属于母公司股东权益合计68,524,143,051.3568,509,809,654.0567,358,648,385.1368,567,457,618.33
股东权益合计80,326,092,964.9380,143,633,572.5278,942,476,886.9579,880,866,892.2
负债和股东权益合计211,972,533,766.8213,146,380,397.62213,317,704,838.46206,035,799,280.43
现金流量表
报告期2023-12-312023-09-302023-06-302023-03-31
经营活动现金流入小计286,783,410,440.97207,172,280,162.62136,202,740,273.0764,274,798,025.94
经营活动现金流出小计281,551,890,713.87204,869,819,552.94134,564,316,325.1566,898,120,438.23
经营活动产生的现金流量净额5,231,519,727.12,302,460,609.681,638,423,947.92-2,623,322,412.29
投资活动现金流入小计29,309,350,002.9525,633,471,281.913,783,614,613.69,564,308,459.63
投资活动现金流出小计31,801,222,841.4728,633,020,869.0416,398,265,181.511,670,525,926.34
投资活动产生的现金流量净额-2,491,872,838.52-2,999,549,587.14-2,614,650,567.9-2,106,217,466.71
筹资活动现金流入小计79,711,765,730.4459,457,575,645.3346,283,919,602.1226,487,446,416.77
筹资活动现金流出小计79,479,914,839.7156,661,634,536.9541,152,299,047.1822,174,397,672.85
筹资活动产生的现金流量净额231,850,890.732,795,941,108.385,131,620,554.944,313,048,743.92
汇率变动对现金及现金等价物的影响-5,580,083.93-60,841,645.22-948,933.06-12,668,704.92
现金及现金等价物净增加额2,965,917,695.382,038,010,485.74,154,445,001.9-429,159,840
期末现金及现金等价物余额27,499,809,001.226,571,901,791.5228,688,336,307.7224,104,731,465.82
最新报告期:2024-04-10
研究机构分析师预测每股收益(元)更新日
2023年2024年2025年
西南证券杜向阳1.471.621.792024-04-10
浙商证券孙建,王帅1.361.551.742024-04-09
中信建投证券刘若飞,贺菊颖1.371.521.702024-04-08
中金公司朱言音1.301.43--2024-04-01
TOP↑